



SHIPMENT OF FIRST IMMUNOXEL ORDER

FOR IMMEDIATE RELEASE

23 April 2009

Australian healthcare company Stirling Products (ASX:STI) is pleased to advise that Ekomed LLC, the Licensor of the Zocap phytopharmaceuticals, has just published an announcement advising the first sale and shipment of Immunoxel product and also a follow-up order outside the Ukraine under the Company's pending joint venture. See: <http://www.prweb.com/releases/2009/04/prweb2345154.htm>

Immunoxel is one of the 26 phytopharmaceutical (botanical) products being commercialised globally under a Zodiac Capital Limited License Agreement that, subject to shareholder approval, the Company has agreed to joint venture with Zodiac Capital as has previously been advised to the market on 25 March 2009. The Company further advises that the Shareholders Meeting which also seeks the approval of director appointments and payments as well as for completion of over \$2 million in funding committed to the Company is scheduled for 29 May, 2009. The Notice of Meeting, Information Memorandum and Independent Experts Reports will be dispatched to all Shareholders early next week.

For further information please contact;

Peter Boonen
Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E; peter.boonen@stirlingproducts.net
www.stirlingproducts.net